Lind AI

What Lind AI does

Lind AI is a healthcare AI company that builds an intelligent clinical trial matching platform for health systems, founded in 2023 by Oggie Nikolic (CEO) and Pranav Singh (CTO). The platform uses large language models and a FHIR-native EHR integration architecture to screen every patient in a health system against every active clinical trial overnight in batch mode, surfacing a prioritized list of eligible candidates each morning with per-criterion evidence pulled directly from the patient's chart and decision audit trails linked into the health record. Lind's TRIAGE system has been peer-reviewed at Atrium Health's NCI-designated cancer center, achieving 94.2% agreement with expert clinical research coordinators across 1,770 adjudicated criteria, with 98.7% sensitivity and 97.6% specificity at a high-sensitivity threshold, and the company reports 97% trial-level accuracy in production.

The platform is deployed across 17M+ patients at three named health system partners (Advocate Health, Atrium Health, and Wake Forest University School of Medicine) covering 86 hospitals and 1,659 clinics, processing 224K+ patient records across 90+ active studies daily. Lind operates a dual-sided business model: enterprise SaaS subscriptions for health systems (quote-based pricing, embedded EHR deployment, and SOC 2 / HIPAA compliance) plus a sponsor-facing Lind Network product for pharma and biotech customers that provides site selection, real-world patient density data, cohort modeling, and protocol optimization. The company has expanded internationally through the Lind Asia joint venture with Precision Medicine Asia (PREMIA) covering Taiwan, Japan, South Korea, Singapore, and Australia, and is supported by advisory board members including former ASCO CMO Dr. Richard Schilsky and former Verily CTO Thomas Stanis. Lind is venture-backed with $5.5M in seed funding from 8VC, Abstract Ventures, and Correlation Ventures, and has graduated from the CancerX Accelerator and Creative Destruction Lab Computational Health programs.

Name

Lind AI

Legal name

Lind AI, Inc.

Website

https://lind.care

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Lind AI provides AI-powered clinical trial matching for health systems, screening every patient against every active trial overnight via FHIR-native EHR integration; deployed across 17M+ patients at three major U.S. health system partners.

Ownership category

akta.pro rank

Product category

Healthcare AI Software (Clinical Trial Matching)

NAICS

Computer Systems Design and Related Services (54151), Other Computer Related Services (541519)

SIC

Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

EHR Extensions, APIs, App Marketplaces & SMART-on-FHIR Apps (HLACAAAN)

akta.pro secondary industries

Decentralized & Hybrid Trial Site Services (Home Health/Nursing) (HLAGACAH), Patient Registries & Chronic Disease Registry Analytics (HLACAHAH)

Keywords

• Clinical trial matching
• Healthcare AI platform
• EHR integration software
• Patient screening automation
• Clinical research infrastructure

Headquarters

HQ city

San Mateo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Health System Platform Subscription: Enterprise SaaS platform subscription for health systems. Lind screens every patient in the health system against every open study nightly, surfacing matches embedded in the EHR with evidence mapped to eligibility criteria. Pricing is quote-based, likely tiered by health system size or patient volume.
2. Sponsor Network Tools: Site network tools for pharma/biotech sponsors to identify high-quality sites, access real-world patient density data, and optimize trial protocols based on eligibility insights and cohort modeling.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Lind AI provides an AI-powered clinical trial matching platform that screens every patient in a health system against every active study nightly and surfaces EHR-embedded match candidates with evidence mapped to eligibility criteria. The platform also offers sponsor tools for site selection, real-world patient density analytics, and protocol optimization. The underlying TRIAGE system uses large language models validated at 94.2% agreement with expert clinical research coordinators across 1,770 adjudicated criteria.

Product overview

Lind AI offers the Lind Platform, a unified clinical trial infrastructure system for health systems. The core product consists of three integrated modules: Health System Tools (for automated patient screening embedded in the EHR), the Lind Network (connecting research-ready sites for sponsors), and Sponsor Tools (for site selection and protocol optimization). Supporting this is the TRIAGE AI technology, which uses LLMs and NLP to match patients to trials with 97% screening accuracy validated against expert oncologists. The platform screens every patient against every study nightly, delivering prioritized match lists by morning with zero added work for coordinators. Deployed across 17M+ patients at 3 health system partners with 86 hospitals and 1,659 clinics.

Differentiator

Problem solved

Functional benefit

Products and services

• Lind Platform An intelligent research platform for health systems that automates clinical trial screening by evaluating every patient against every open study nightly, surfacing EHR-native matches with evidence mapped to eligibility criteria. FHIR-native and disease-agnostic, supporting oncology, dermatology, hematology, neurology and beyond. Sold to hospital systems and academic medical centers.
• Lind Network A growing network of research-ready sites with verified patient populations that enables pharma/biotech sponsors to identify high-quality sites, access real-world patient density data, and compress time to enrollment. Each health system added increases the network's value. Sold to pharmaceutical and biotech sponsors.

Quantifiable outcome

• 97% trial-level accuracy in matching expert oncologist review
• +5 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Partnerships

13 partnerships are on record, tiered core and flagship.

• Advocate HealthcoreStrategic or Co-development Partner · 27 May 2026Partnered to improve clinical trial matching for cancer patients using Lind's AI platform. Retrospective study demonstrated 94%+ agreement with clinical reviewers. Advocate Health is launching first prospective trial with Wake Forest University School of Medicine as academic core. Partnership began in oncology and expanding to other diseases. In 2025, screened nearly 1 million patients across 130+ clinics.
• Precision Medicine Asia (PREMIA)coreStrategic or Co-development Partner · 27 May 2026Formed Lind Asia joint venture to bring AI-powered trial screening to Asia-Pacific countries: Taiwan, Japan, South Korea, Singapore, and Australia. Lind Asia is exclusive regional partner for Lind's platform with three pillars: AI patient identification, research-ready site network, integrated molecular profiling.
• Wake Forest University School of MedicinecoreStrategic or Co-development Partner · 20 October 2025Academic core partner for Advocate Health's first prospective trial of Lind's platform, evaluating whether AI matching can increase patient screening and successful enrollment in clinical trials.
• National Cancer Institute (NCI)flagshipStrategic or Co-development Partner · 25 April 2025Collaboration on AACR Abstract LB373 applying LLMs and ML to 12,096 oncology trials. Framework predicts trial completion with ~81% accuracy and identifies how protocol quality affects enrollment success. Led by co-founders with Richard L. Schilsky as collaborator.
• Dr. Richard SchilskyflagshipOthers · 15 January 2025Advisory Board member. Former ASCO Chief Medical Officer and EVP. Led clinical affairs, guidelines, and quality programs. Former Chief of Hematology/Oncology at University of Chicago. Chair of CALGB at NCI. Foremost voice in clinical trial design, conduct, and policy.
• Amy ChangflagshipOthers · 15 January 2025Advisory Board member. Serves on boards of Salesforce, Procter & Gamble, and Disney. Founded AI-driven relationship intelligence platform Accompany (acquired by Cisco). Former SVP leading Cisco's Collaboration unit. Deep expertise in AI product strategy, enterprise GTM, and scaling technology businesses.
• Thomas StanisflagshipOthers · 15 January 2025Advisory Board member. Former CTO of Verily (Google Life Sciences) and VP Engineering at Google. Led technical organization building health data platforms, clinical research tools, and regulatory-grade software for life sciences. Expertise in HIPAA-compliant data pipelines and FDA-adjacent software quality.
• Creative Destruction Lab (CDL)flagshipStrategic or Co-development Partner · 1 October 2024Selected for nine-month Computational Health program at UW Foster School of Business. Mentors from Microsoft, Washington Research Foundation, Cooley LLP, and UW Allen School. Clinical research mentorship anchored by Gilead Sciences and Fred Hutch Cancer Center. CDL is no-fee and takes no equity.
• Gilead SciencesflagshipStrategic or Co-development Partner · 1 October 2024Lead clinical research mentor for Lind's participation in CDL Computational Health program, providing strategic guidance on sponsor perspective, site selection, feasibility, and protocol design.
• Fred Hutch Cancer CenterflagshipStrategic or Co-development Partner · 1 October 2024Lead clinical research mentor alongside Gilead Sciences for Lind's CDL Computational Health participation, contributing expertise in clinical trial design and oncology research.
• CancerX AcceleratorflagshipStrategic or Co-development Partner · 26 February 2024Selected as one of 16 startups in inaugural CancerX Accelerator cohort under White House Cancer Moonshot. Program provided access to nine Champion organizations (UC Davis Health, Atrium, Debiopharm, Reveal HealthTech, Dell, Intel, AstraZeneca, AWS, Oncology Ventures), 60+ mentors, federal partners. Led to enterprise contracts with Champion health systems.
• Atrium HealthcoreStrategic or Co-development Partner · 26 February 2024Champion organization in CancerX Accelerator providing live environment to pressure-test Lind's platform against real workflows and data. Conducted peer-reviewed validation of TRIAGE system across 168 oncology trials and 806 patients at NCI-designated cancer center.
• Moffitt Cancer CenterflagshipStrategic or Co-development Partner · 26 February 2024Co-host of CancerX Accelerator alongside DiMe and co-host of CancerX Moffitt Innovation Summit. Lind invited as Alumni for fireside chat on scaling from validation to enterprise deployment.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Flatiron Health: Flatiron Health (acquired by Roche) provides real-world oncology data and clinical research technology used by health systems, sponsors, and academic medical centers. Overlaps with Lind in oncology trial infrastructure and EHR data extraction, with a much larger and more established footprint.
• IQVIA: IQVIA is the largest CRO and healthcare data incumbent, offering trial feasibility, site selection, and patient recruitment solutions including AI-driven matching. While much broader in scope than Lind, IQVIA competes for sponsor-side budget on site selection and protocol optimization.
• Tempus AI: Tempus AI combines molecular profiling, real-world data, and an AI-enabled clinical trial matching platform (Lens) for oncology. Overlaps with Lind on AI trial matching and integrates EHR-based patient identification, but operates at much larger scale with broader molecular diagnostics offerings.
• Medidata (Dassault Systèmes): Medidata provides the dominant clinical trial technology platform used by major pharma sponsors, including trial design, EDC, and increasingly AI-driven patient recruitment tools. A broad incumbent that competes with Lind for sponsor budget and could potentially integrate similar trial-matching capabilities.
• Verily (Alphabet): Verily operates clinical research platforms including site network, real-world evidence, and decentralized trial capabilities under Alphabet. Comparable to Lind in building AI-driven trial infrastructure and is a potential strategic acquirer given Lind's clinical validation and APAC footprint.
• Veeva Systems: Veeva is the leading clinical trial technology platform serving pharma sponsors and CROs across CTMS, EDC, and trial operations. Comparable to Lind in addressing pharma-side workflow needs but with a much broader and established product portfolio.

Direct peers

• BEKHealth: BEKHealth provides an AI-driven clinical trial matching platform that integrates with health system EHRs to identify eligible patients. Comparable to Lind in targeting community health systems and academic medical centers with embedded pre-screening workflows.
• Mendel: Mendel applies LLMs to clinical and biomedical text to structure patient data and match patients to clinical trials. Overlaps directly with Lind's LLM-based eligibility screening and serves similar pharma sponsor and health system use cases, making it a head-to-head AI trial-matching competitor.
• Deep 6 AI: Deep 6 AI is the most direct competitor to Lind AI, offering an AI-powered clinical trial matching platform that mines EHR data to surface eligible patients. Both companies target health systems with FHIR-native integration and compete on accuracy, EHR integration depth, and health system reference customers.

Emerging players

• Antidote (formerly TrialReach): Antidote provides a clinical trial matching platform with a strong patient-facing search and EHR-based prescreening component. It overlaps with Lind on health system integration and patient-trial matching but historically differentiated with consumer-facing trial discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lind-ai

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lind AI